GSK's CEO Emma Walmsley will step down in December and be replaced by insider Luke Miels, the British drugmaker said on Monday, tasking the new leader to deliver shareholder value and prepare for the ...
GlaxoSmithKline (GSK) researchers at work in an R&D laboratory at the company's Stevenage, U.K., site. GSK has agreed to acquire Rapt Therapeutics for $2.2 billion, in a deal intended to bolster the ...
Unknown litigation costs have cast a cloud over wide-moat GSK GSK since 2020, when the US Food and Drug Administration requested that Zantac be taken off the market. But earlier this month, GSK ...
GlaxoSmithKline (GSK) will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology, and inflammation (RI&I) as well as oncology, through a collaboration ...
GSK plc announces its CEO transition, with CCO Luke Miels to succeed Emma Walmsley, as shares rise 3% and the company maintains a 4% dividend yield. GSK's strengths include its HIV, vaccines, and ...
The pharmaceutical industry faces significantly longer lead times than other industries, and time delays can seriously impact the health outcomes of countless individuals. Recognizing the potential ...
GSK plc (NYSE:GSK) is included among the 15 Global Dividend Stocks to Diversify Your Portfolio. On December 10, HSBC analyst Rajesh Kumar raised the firm’s price target on GSK plc (NYSE:GSK) to 1,500 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results